Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAAD for Prevention of Surgical Site Infection
NCT03226626Phase 3Unknown
- Sponsor
- HK Surgical
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Reversible Covalent Inhibitors
01
Overview
Phase 3, randomised, open-label trial of cefazolin and metronidazole in surgical site infection (SSI), venous thromboembolism (VTE) and sepsis (2 arms), sponsored by HK Surgical. Primary endpoints: Surgical Site Infection at 30 days, Venous Thromboembolism at 30 days and 2 more. Status: unknown.
02
Drugs
cefazolinmetronidazole
03
Conditions
surgical site infection (SSI)venous thromboembolism (VTE)sepsis
Beyond the preview
Go deeper on NCT03226626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226626.